CelLBxHealth (CLBX) Aperçu de l'action
ANGLE plc, société de diagnostic médical, développe des produits de diagnostic du cancer au Royaume-Uni, en Europe, en Amérique du Nord et dans le monde entier. Plus de détails
| Score flocon de neige | |
|---|---|
| Évaluation | 0/6 |
| Croissance future | 2/6 |
| Performances passées | 0/6 |
| Santé financière | 4/6 |
| Dividendes | 0/6 |
Récompenses
Analyse des risques
+ 2 plus de risques
CLBX Community Fair Values
Create NarrativeSee what others think this stock is worth. Follow their fair value or set your own to get alerts.
Analyst Price Targets
CelLBxHealth plc Concurrents
Historique des prix et performances
| Historique des cours de bourse | |
|---|---|
| Prix actuel de l'action | UK£0.013 |
| Plus haut sur 52 semaines | UK£0.08 |
| Plus bas sur 52 semaines | UK£0.0085 |
| Bêta | 0.41 |
| Variation sur 1 mois | -6.90% |
| Variation sur 3 mois | 31.71% |
| Variation sur 1 an | -74.29% |
| Variation sur 3 ans | -89.41% |
| Variation sur 5 ans | -98.87% |
| Évolution depuis l'introduction en bourse | -99.10% |
Nouvelles et mises à jour récentes
Recent updates
Mise à jour du récit • Jun 22
CLBX: Lung Cancer Study And Big Pharma Agreement Will Drive Future Upside
Analysts have kept their fair value estimate for CelLBxHealth steady at £0.04, with only marginal adjustments to assumptions on discount rate, revenue growth, profit margin and future P/E feeding into the latest price target update. What's in the News CelLBxHealth PLC entered into a Master Services Agreement with AstraZeneca PLC, establishing CelLBxHealth as a qualified service provider to support drug discovery and development using CTC powered analytics of clinical trial samples with the Parsortix platform.Mise à jour du récit • Jun 05
CLBX: Lung Cancer Study Will Support Future Upside Narrative
Analysts have maintained their fair value estimate for CelLBxHealth at £0.04 per share. A slightly lower discount rate and marginal adjustments to assumptions for revenue growth, profit margin and future P/E have resulted in an unchanged price target.Mise à jour du récit • May 22
CLBX: Lung Cancer Study And New Sales Leadership Will Drive Upside
Analysts have slightly revised their price target for CelLBxHealth, keeping fair value at £0.04 while fine tuning assumptions around the discount rate, revenue growth, profit margin and future P/E to reflect updated expectations for the business. What's in the News CelLBxHealth issued revenue guidance for fiscal 2026, indicating an expectation of at least £2.1 million, described as a 50% increase on fiscal 2025, alongside ongoing cost reduction efforts (Corporate Guidance).Mise à jour du récit • May 04
CLBX: Lung Cancer Collaboration And Cost Discipline Will Support Future Upside
Analysts have reduced their price target for CelLBxHealth from £0.07 to £0.04. This reflects updated assumptions around discount rates, profit margins, and a lower future P/E multiple.
Mise à jour du récit • Apr 19
CLBX: Regulatory Streamlining And Refocused Resources Will Support Future Upside Potential
Analysts have adjusted their price target on CelLBxHealth, highlighting higher assumed revenue growth, a wider profit margin and a lower future P/E multiple as key inputs to their revised fair value view. What's in the News CelLBxHealth decided to discontinue maintenance of its FDA establishment license and device listing for the Parsortix system, aligning its regulatory approach with current operational and commercial priorities (Key Developments).Mise à jour du récit • Apr 04
CLBX: Cost Discipline And Refocused Regulatory Approach Will Support Future Oncology Upside
Analysts have kept their fair value estimate for CelLBxHealth steady at £0.07 per share, with a slightly higher discount rate and a small adjustment to long term profit margin and future P/E assumptions guiding this latest price target update. What's in the News CelLBxHealth decided to discontinue maintenance of its FDA establishment license and device listing for the Parsortix system, aligning its regulatory approach with current operational and commercial priorities while focusing on cost discipline (Key Developments).Mise à jour du récit • Mar 20
CLBX: Cost Discipline And Regulatory Streamlining Will Support Future Oncology Upside
CellBxHealth’s analyst price target has been reset to £0.07. Analysts attribute this to consistent fair value assumptions, a slightly lower discount rate, a marginally higher profit margin outlook, and a modestly reduced future P/E multiple.Mise à jour du récit • Mar 06
CLBX: Cost Discipline And Refocused Resources Will Support Oncology Upside
Analysts have modestly raised their price target on CelLBxHealth, citing an unchanged intrinsic value estimate of about £0.07 per share, slightly higher assumed discount rates, a marginally higher future P/E expectation, and a small reduction in projected profit margins. What's in the News CelLBxHealth plc decided to discontinue maintenance of its FDA establishment license and device listing for the Parsortix system, aligning regulatory obligations with current operational and commercial priorities (Key Developments).Mise à jour du récit • Feb 19
CLBX: Equity Raises And Lower Risk Profile Will Support Oncology Upside
Analysts have raised their target price for CelLBxHealth to £0.07. The updated view reflects revised assumptions around the discount rate, profit margin, revenue growth, and future P/E multiples.
Mise à jour du récit • Feb 05
CLBX: Future Repricing Will Rely On Equity Raises And Margin Expansion
Analysts have raised their price target for CelLBxHealth, citing slightly lower assumed discount rates, a modest uptick in projected revenue growth and profit margins, and a reduced future P/E of about 45x as the main factors behind the change. What's in the News CelLBxHealth completed a follow-on equity offering of £7.208915 million, issuing multiple blocks of ordinary shares at £0.01 per share.Mise à jour du récit • Jan 22
CLBX: Equity Raises And QIAGEN Alliance Will Support Future Upside Potential
Analysts have trimmed their fair value estimate for CelLBxHealth from US$0.17 to US$0.04. This reflects updated assumptions around revenue growth, profit margins, discount rate and future P/E expectations.Mise à jour du récit • Jan 08
CLBX: Future Profitability Assumptions Will Drive Bullish Repricing Potential
Analysts have reduced their price targets on CelLBxHealth, citing updates to fair value assumptions, a higher discount rate, more moderate revenue growth expectations, improved profit margin estimates toward 9.49%, and a revised future P/E of about 53.37x. What's in the News CelLBxHealth plc has filed follow on equity offerings totaling £8.67 million across multiple tranches of ordinary shares at £0.01, including securities with a subsequent direct listing feature.Mise à jour du récit • Dec 23
CLBX: Equity Raises Will Drive Future Oncology Partnerships And Upside Potential
Analysts have nudged their price target on CelLBxHealth slightly higher to reflect updated valuation models, with modest adjustments to the discount rate, long term profit margin expectations, and forward earnings multiples. These revisions now support an intrinsic value estimate of approximately $0.07 per share.Mise à jour du récit • Dec 09
CLBX: Equity Raises Will Fund Future Oncology Partnerships And Upside Potential
Analysts have lowered their price target on CelLBxHealth from approximately $0.11 to $0.07 per share, citing a higher required discount rate, more conservative long term revenue growth assumptions, and a higher future P/E multiple that together point to a more tempered outlook for upside. What's in the News CelLBxHealth completed a £7.21 million follow on equity offering, issuing over 720 million ordinary shares at £0.01 per share, alongside a subsequent direct listing (company filing).Mise à jour du récit • Nov 25
CLBX: New Partnerships And Equity Raise Will Drive 2025 Performance
Narrative Update on CelLBxHealth Analysts have maintained CelLBxHealth's target price at $0.11 per share, citing improved profit margin estimates and a slightly higher discount rate in their updated valuation model. What's in the News Entered a non-exclusive collaboration and co-marketing agreement with QIAGEN Manchester Ltd., allowing the Parsortix platform to be offered in pharmaceutical projects that combine CTC enrichment and molecular analysis tools (Key Developments) Completed a follow-on equity offering totaling £6.8 million through the issuance of common stock (Key Developments) Filed additional follow-on equity offerings amounting to £1 million and £8.67 million to raise further capital (Key Developments) Special/Extraordinary Shareholders Meeting scheduled for December 15, 2025, in London (Key Developments) Changed company name from ANGLE plc to CelLBxHealth plc effective October 29, 2025 (Key Developments) Valuation Changes Fair Value estimate remains stable at $0.105 per share, showing no change from previous assessments.Mise à jour du récit • Nov 10
CLBX: Revenue Shifts And Leadership Changes Will Shape 2025 Outlook
Analysts have revised their price target for CelLBxHealth, maintaining the fair value at $0.105. Adjustments in the discount rate reflect a reassessment of market conditions and risk profiles.Mise à jour du récit • Oct 27
Leadership Appointment And Diagnostic Partnerships Will Shape Future Market Expansion
Analysts have maintained ANGLE's fair value estimate at $0.11 per share. Their outlook remains steady after a review of updated company fundamentals and underlying discount rates.Mise à jour du récit • Oct 13
Pharma Partnerships And Liquid Biopsy Will Expand Future Markets
Analysts have lowered their price target for ANGLE from $0.17 to $0.105. They cite updated projections of higher revenue growth, but reduced profit margins and a higher discount rate are impacting the company's fair value assessment.Mise à jour du récit • Sep 11
Pharma Partnerships And Liquid Biopsy Will Expand Future Markets
Despite a substantial increase in consensus revenue growth forecasts, ANGLE’s future P/E multiple has halved, reflecting a notable de-rating and driving the fair value estimate down from £0.28 to £0.17. What's in the News ANGLE plc announced a collaboration with Myriad Genetics, utilising ANGLE's Parsortix system to process cancer patient blood samples for molecular analysis, comparing CTC-DNA with matched tissue samples via Myriad's assay; further details remain confidential.Nouveau récit • Jun 01
Pharma Partnerships And Liquid Biopsy Will Expand Future Markets
ANGLE's unique technologies and partnerships in precision oncology position it for strong, margin-expanding revenue growth as liquid biopsy adoption accelerates.Article d’analyse • May 30
Is ANGLE (LON:AGL) In A Good Position To Invest In Growth?
Just because a business does not make any money, does not mean that the stock will go down. For example, biotech and...Article d’analyse • Jan 22
Here's Why We're Watching ANGLE's (LON:AGL) Cash Burn Situation
Even when a business is losing money, it's possible for shareholders to make money if they buy a good business at the...Article d’analyse • Sep 27
Will ANGLE (LON:AGL) Spend Its Cash Wisely?
We can readily understand why investors are attracted to unprofitable companies. For example, biotech and mining...Article d’analyse • Mar 20
We're Keeping An Eye On ANGLE's (LON:AGL) Cash Burn Rate
Just because a business does not make any money, does not mean that the stock will go down. For example, biotech and...Article d’analyse • Dec 02
Will ANGLE (LON:AGL) Spend Its Cash Wisely?
We can readily understand why investors are attracted to unprofitable companies. For example, although Amazon.com made...Article d’analyse • Aug 11
We Think ANGLE (LON:AGL) Needs To Drive Business Growth Carefully
Even when a business is losing money, it's possible for shareholders to make money if they buy a good business at the...Article d’analyse • Feb 28
We Think ANGLE (LON:AGL) Needs To Drive Business Growth Carefully
Just because a business does not make any money, does not mean that the stock will go down. For example, although...Article d’analyse • Jul 16
ANGLE (LON:AGL) Is In A Good Position To Deliver On Growth Plans
We can readily understand why investors are attracted to unprofitable companies. For example, biotech and mining...Rendement pour les actionnaires
| CLBX | GB Medical Equipment | GB Marché | |
|---|---|---|---|
| 7D | 5.9% | -1.4% | 0.9% |
| 1Y | -74.3% | -9.7% | 19.6% |
Rendement vs Industrie: CLBX a sous-performé le secteur UK Medical Equipment qui a rapporté -9.7 % au cours de l'année écoulée.
Rendement vs marché: CLBX a sous-performé le marché UK qui a rapporté 19.6 % au cours de l'année écoulée.
Volatilité des prix
| CLBX volatility | |
|---|---|
| CLBX Average Weekly Movement | 16.5% |
| Medical Equipment Industry Average Movement | 5.5% |
| Market Average Movement | 5.1% |
| 10% most volatile stocks in GB Market | 10.4% |
| 10% least volatile stocks in GB Market | 2.7% |
Cours de l'action stable: Le cours de l'action de CLBX a été volatil au cours des 3 derniers mois par rapport au marché UK.
Volatilité au fil du temps: La volatilité hebdomadaire de CLBX ( 17% ) est restée stable au cours de l'année écoulée, mais reste supérieure à 75 % des actions de UK.
À propos de l'entreprise
| Fondée | Salariés | PDG | Site web |
|---|---|---|---|
| 1994 | 114 | n/a | cellbxhealth.com |
ANGLE plc, société de diagnostic médical, développe des produits de diagnostic du cancer au Royaume-Uni, en Europe, en Amérique du Nord et au niveau international. La société développe les systèmes Parsortix PC1, un dispositif médical pour la capture et la récolte de cellules tumorales circulantes (CTC) intactes à partir du sang de patientes atteintes d'un cancer du sein métastatique, en vue d'une analyse ultérieure validée par l'utilisateur. Elle propose également le Portrait+ CTC Staining kit, un kit de laboratoire prêt à l'emploi doté d'une sensibilité et d'une spécificité analytiques élevées pour l'identification, la caractérisation et le dénombrement des transitions épithéliales et mésenchymateuses, ainsi que CellKeep Slide, une technologie de collecte des CTC.
CelLBxHealth plc Résumé des fondamentaux
| CLBX statistiques fondamentales | |
|---|---|
| Capitalisation boursière | UK£15.34m |
| Bénéfices(TTM) | -UK£12.94m |
| Recettes(TTM) | UK£1.15m |
13.3x
Ratio P/S-1.2x
Ratio P/ELe site CLBX est-il surévalué ?
Voir Juste valeur et analyse de l'évaluationBénéfices et recettes
| CLBX compte de résultat (TTM) | |
|---|---|
| Recettes | UK£1.15m |
| Coût des recettes | UK£1.49m |
| Marge brute | -UK£333.00k |
| Autres dépenses | UK£12.61m |
| Les revenus | -UK£12.94m |
Derniers bénéfices déclarés
Jun 30, 2026
Prochaine date de publication des résultats
s/o
| Résultat par action (EPS) | -0.011 |
| Marge brute | -28.91% |
| Marge bénéficiaire nette | -1,123.44% |
| Ratio dettes/capitaux propres | 0% |
Quelles ont été les performances à long terme de CLBX?
Voir les performances historiques et les comparaisonsAnalyse de l'entreprise et données financières
| Données | Dernière mise à jour (heure UTC) |
|---|---|
| Analyse de l'entreprise | 2026/08/07 19:16 |
| Cours de l'action en fin de journée | 2026/08/07 00:00 |
| Les revenus | 2026/06/30 |
| Revenus annuels | 2025/12/31 |
Sources de données
Les données utilisées dans notre analyse de l'entreprise proviennent de S&P Global Market Intelligence LLC. Les données suivantes sont utilisées dans notre modèle d'analyse pour générer ce rapport. Les données sont normalisées, ce qui peut entraîner un délai avant que la source ne soit disponible.
| Paquet | Données | Cadre temporel | Exemple de source américaine * |
|---|---|---|---|
| Finances de l'entreprise | 10 ans |
| |
| Estimations consensuelles des analystes | +3 ans |
|
|
| Prix du marché | 30 ans |
| |
| Propriété | 10 ans |
| |
| Gestion | 10 ans |
| |
| Principaux développements | 10 ans |
|
* Exemple pour les titres américains ; pour les titres non américains, des formulaires réglementaires et des sources équivalentes sont utilisés.
Sauf indication contraire, toutes les données financières sont basées sur une période annuelle mais mises à jour trimestriellement. C'est ce qu'on appelle les données des douze derniers mois (TTM) ou des douze derniers mois (LTM). En savoir plus.
Modèle d'analyse et flocon de neige
Les détails du modèle d’analyse utilisé pour générer ce rapport sont disponibles sur notre page Github ; nous proposons également des guides sur la façon d’utiliser nos rapports et des tutoriels sur YouTube.
Découvrez l'équipe de classe mondiale qui a conçu et construit le modèle d'analyse Simply Wall St.
Indicateurs de l'industrie et du secteur
Nos indicateurs de secteur et de section sont calculés toutes les 6 heures par Simply Wall St. Les détails de notre processus sont disponibles sur Github.
Sources des analystes
CelLBxHealth plc est couverte par 4 analystes. 2 de ces analystes ont soumis les estimations de revenus ou de bénéfices utilisées comme données d'entrée dans notre rapport. Les soumissions des analystes sont mises à jour tout au long de la journée.
| Analyste | Institution |
|---|---|
| Adam McCarter | Cavendish |
| Lucy Codrington | Edison Investment Research |
| Lucy Codrington | Jefferies LLC |